Thermo Fisher Scientific Inc. (NYSE:TMO) Shares Sold by Webster Bank N. A.

Webster Bank N. A. decreased its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 2.9% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 18,400 shares of the medical research company’s stock after selling 547 shares during the quarter. Thermo Fisher Scientific comprises about 1.0% of Webster Bank N. A.’s portfolio, making the stock its 19th biggest holding. Webster Bank N. A.’s holdings in Thermo Fisher Scientific were worth $9,572,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Daymark Wealth Partners LLC boosted its holdings in shares of Thermo Fisher Scientific by 24.5% during the 2nd quarter. Daymark Wealth Partners LLC now owns 619 shares of the medical research company’s stock worth $342,000 after purchasing an additional 122 shares during the last quarter. Kathmere Capital Management LLC acquired a new position in Thermo Fisher Scientific during the second quarter worth $375,000. Driehaus Capital Management LLC increased its stake in shares of Thermo Fisher Scientific by 75.0% in the 2nd quarter. Driehaus Capital Management LLC now owns 1,524 shares of the medical research company’s stock worth $843,000 after acquiring an additional 653 shares during the last quarter. Ascent Group LLC raised its holdings in shares of Thermo Fisher Scientific by 5.4% during the 2nd quarter. Ascent Group LLC now owns 11,029 shares of the medical research company’s stock worth $6,099,000 after acquiring an additional 561 shares during the period. Finally, Aviso Wealth Management grew its holdings in shares of Thermo Fisher Scientific by 9.9% in the second quarter. Aviso Wealth Management now owns 1,596 shares of the medical research company’s stock valued at $883,000 after purchasing an additional 144 shares during the period. 89.23% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Thermo Fisher Scientific

In related news, CEO Marc N. Casper sold 10,000 shares of the firm’s stock in a transaction dated Monday, December 2nd. The shares were sold at an average price of $530.26, for a total value of $5,302,600.00. Following the completion of the sale, the chief executive officer now owns 111,192 shares in the company, valued at $58,960,669.92. This trade represents a 8.25 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Over the last quarter, insiders sold 34,850 shares of company stock valued at $19,123,197. 0.34% of the stock is owned by company insiders.

Analysts Set New Price Targets

Several research firms have weighed in on TMO. TD Cowen boosted their target price on shares of Thermo Fisher Scientific from $656.00 to $686.00 in a report on Tuesday, October 22nd. Barclays cut their target price on Thermo Fisher Scientific from $620.00 to $610.00 and set an “equal weight” rating for the company in a research note on Wednesday, October 23rd. Evercore ISI lowered their price target on Thermo Fisher Scientific from $630.00 to $620.00 and set an “outperform” rating for the company in a report on Thursday, October 24th. Bernstein Bank upped their target price on shares of Thermo Fisher Scientific from $565.00 to $625.00 and gave the company a “market perform” rating in a research report on Tuesday, October 22nd. Finally, StockNews.com raised Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a research report on Tuesday, January 14th. Four equities research analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $648.95.

Thermo Fisher Scientific Stock Up 0.1 %

Shares of Thermo Fisher Scientific stock opened at $575.21 on Monday. Thermo Fisher Scientific Inc. has a one year low of $493.30 and a one year high of $627.88. The firm has a fifty day moving average of $533.60 and a two-hundred day moving average of $569.81. The company has a market cap of $220.02 billion, a P/E ratio of 36.06, a PEG ratio of 3.82 and a beta of 0.76. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.26 and a current ratio of 1.63.

Thermo Fisher Scientific announced that its Board of Directors has approved a stock buyback program on Friday, November 15th that permits the company to buyback $4.00 billion in outstanding shares. This buyback authorization permits the medical research company to buy up to 2% of its shares through open market purchases. Shares buyback programs are often a sign that the company’s board of directors believes its shares are undervalued.

Thermo Fisher Scientific Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, January 15th. Investors of record on Friday, December 13th were issued a dividend of $0.39 per share. This represents a $1.56 dividend on an annualized basis and a yield of 0.27%. The ex-dividend date of this dividend was Friday, December 13th. Thermo Fisher Scientific’s dividend payout ratio is presently 9.78%.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.